Sat Kartar Life Ltd
Incorporated in June 2012, Sat Kartar Shopping Limited is an Ayurveda healthcare company that delivers natural wellness solutions for therapeutic and lifestyle products.[1]
- Market Cap ₹ 190 Cr.
- Current Price ₹ 120
- High / Low ₹ 220 / 116
- Stock P/E 11.1
- Book Value ₹ 42.9
- Dividend Yield 0.58 %
- ROCE 37.3 %
- ROE 28.7 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 163 | 201 | |
| 149 | 176 | |
| Operating Profit | 14 | 25 |
| OPM % | 9% | 12% |
| 1 | 2 | |
| Interest | 1 | 1 |
| Depreciation | 1 | 3 |
| Profit before tax | 13 | 23 |
| Tax % | 25% | 26% |
| 10 | 17 | |
| EPS in Rs | 6.24 | 10.86 |
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 74% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -31% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 29% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 16 | 16 |
| Reserves | 36 | 52 |
| 6 | 2 | |
| 7 | 15 | |
| Total Liabilities | 65 | 85 |
| 6 | 12 | |
| CWIP | 0 | 0 |
| Investments | 1 | 1 |
| 58 | 72 | |
| Total Assets | 65 | 85 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| -5 | 0 | |
| -0 | -9 | |
| 34 | -1 | |
| Net Cash Flow | 28 | -9 |
| Free Cash Flow | -10 | -7 |
| CFO/OP | -36% | 2% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 13 | 26 |
| Inventory Days | 185 | 264 |
| Days Payable | 170 | 298 |
| Cash Conversion Cycle | 29 | -7 |
| Working Capital Days | 31 | 58 |
| ROCE % | 37% |
Insights
In beta| Mar 2025 | Mar 2026 | |
|---|---|---|
| Average Ticket Size INR ・Standalone data |
|
|
| Daily Unique Leads leads/day ・Standalone data |
||
| Hospital Bed Capacity beds ・Standalone data |
||
| Number of SKUs SKUs ・Standalone data |
||
| Pincodes Served pincodes ・Standalone data |
||
| Repeat Customer % % ・Standalone data |
||
| South India Revenue Share % ・Standalone data |
||
| Team Strength employees ・Standalone data |
||
Extracted by Screener AI
Documents
Announcements
-
Capacity addition
5 August 2026 - Company proposes 10–15 bed hospital-cum-therapy centre in Gurugram, ₹1 crore investment, by 15 October 2026.
-
General Updates
5 August 2026 - Plans new 10-15 bed hospital-cum-therapy centre in Gurugram by 15 October 2026.
-
Copy of Newspaper Publication
4 August 2026 - AGM notice published; 14th AGM on August 28, 2026, with e-voting from August 25-27.
-
General Updates
3 August 2026 - 14th AGM on August 28, 2026; annual report 2025-2026 shared with non-registered email shareholders.
-
Shareholders meeting
3 August 2026 - 14th AGM on 28 Aug 2026 via VC/OAVM; final dividend 70 paise per share, record date 21 Aug 2026.
Annual reports
Concalls
-
May 2026Transcript PPT
-
May 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptPPT
-
Nov 2025Transcript PPT REC
-
Oct 2025TranscriptAI SummaryPPT
-
May 2025Transcript PPT REC
Business Model[1]
The company operates in the Ayurveda healthcare sector using a Direct-to-Consumer (D2C) model, combining Ayurvedic principles with modern research. It focuses on product innovation, branding, and marketing while outsourcing manufacturing to trusted partners, adopting an asset-light strategy.